{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Derma-Hc", "atopic dermatitis", "dry skin", "keratinocyte", "lichenification"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "33652999", "DateCompleted": {"Year": "2021", "Month": "04", "Day": "19"}, "DateRevised": {"Year": "2024", "Month": "06", "Day": "17"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "02", "Day": "26"}], "Language": ["eng"], "ELocationID": ["2359", "10.3390/ijms22052359"], "Journal": {"ISSN": "1422-0067", "JournalIssue": {"Volume": "22", "Issue": "5", "PubDate": {"Year": "2021", "Month": "Feb", "Day": "26"}}, "Title": "International journal of molecular sciences", "ISOAbbreviation": "Int J Mol Sci"}, "ArticleTitle": "Derma-Hc, a New Developed Herbal Formula, Ameliorates Cutaneous Lichenification in Atopic Dermatitis.", "Abstract": {"AbstractText": ["Atopic dermatitis (AD) is a chronic cutaneous disorder that is characterized by severe eczematous inflammation, swelling, and lichenification. Activation of T helper (Th)-22 cells by allergens leads to epidermal hyperplasia with hyperkeratosis at the chronic phase of AD. Derma-Hc is composed of five natural herbs with anti-AD effects, such as <i>Astragalus membranaceus</i> BUNGE, <i>Schizonepeta tenuifolia</i> Briq., <i>Cryptotympana pustulata</i> Fabr., <i>Angelica sinensis</i> Diels, <i>Arctium lappa</i> L. In this study, the ameliorative effect of Derma-Hc on cutaneous lichenification in 2,4-dinitrochlorobenzne (DNCB)-induced AD was investigated. The dorsal skin of mice was sensitized with DNCB to induce AD-like skin lesions. The dermatitis score and frequency of scratching were evaluated. Thickness of epidermis and dermis was measured by staining with H&E. In addition, infiltration of the mast cell was observed by staining with toluidine blue. Then, desmosomal cadherin, DSC1 was examined by immunofluorescence. Pathological mechanisms involved in lichenification were analyzed in AD-like skin lesions and TNF-\u03b1 + IFN-\u03b3-treated with human keratinocytes including keratinocyte differentiation genes and JAK1-STAT3 signaling pathway with IL-22 by RT-PCR and western blotting. Topical treatment of Derma-Hc improved AD-like symptoms such as dryness, edema and lichenefication and decreased the number of scratches. Histopathological analysis demonstrated that Derma-Hc significantly inhibited epidermal hyperplasia, hyperkeratosis, and mast cells infiltration. In addition, the level of DSC1 was highly expressed in the epidermis by Derma-Hc. Moreover, mRNA expression level of FLG, an epidermal differentiation complex gene, was recovered by Derma-Hc treatment. KLK5 and KLK7 were markedly reduced to normalize keratinocyte differentiation in dorsal skin tissues and human keratinocytes. On the other hand, Derma-Hc restored expression level of SPINK5. In addition, Derma-Hc inhibited IL-22 via the blockade of JAK1-STAT3 signal pathway. Taken together, Derma-Hc, a natural herbal formula, regulated keratinocyte differentiation and inhibited epidermal hyperplasia with hyperkeratosis. Therefore, Derma-Hc could be a promising candidate for treating chronic AD through modulating signaling of IL-22-associated skin lichenification."]}, "AuthorList": [{"Identifier": ["0000-0001-7664-3262"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Convergence Korean Medical Science, College of Korean Medicine, Kyung Hee University, Seoul 02447, Korea."}], "LastName": "Nam", "ForeName": "Yeon Kyung", "Initials": "YK"}, {"Identifier": ["0000-0001-6455-5441"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Convergence Korean Medical Science, College of Korean Medicine, Kyung Hee University, Seoul 02447, Korea."}], "LastName": "Kim", "ForeName": "Mi Hye", "Initials": "MH"}, {"Identifier": ["0000-0002-9210-1401"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Korean Medicine Clinical Trial Center, Kyung Hee University Korean Medicine Hospital, Kyung Hee University, Seoul 02454, Korea."}], "LastName": "Ha", "ForeName": "In Jin", "Initials": "IJ"}, {"Identifier": ["0000-0001-5308-2386"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Convergence Korean Medical Science, College of Korean Medicine, Kyung Hee University, Seoul 02447, Korea."}], "LastName": "Yang", "ForeName": "Woong Mo", "Initials": "WM"}], "GrantList": [{"GrantID": "HI19C0264", "Agency": "Korea Health Industry Development Institute", "Country": "Republic of Korea"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Int J Mol Sci", "NlmUniqueID": "101092791", "ISSNLinking": "1422-0067"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "FLG protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "Filaggrin Proteins"}, {"RegistryNumber": "0", "NameOfSubstance": "Plant Extracts"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["drug therapy", "pathology"], "DescriptorName": "Dermatitis, Atopic"}, {"QualifierName": [], "DescriptorName": "Filaggrin Proteins"}, {"QualifierName": ["drug effects", "pathology"], "DescriptorName": "Keratinocytes"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "Mice, Inbred BALB C"}, {"QualifierName": ["chemistry", "therapeutic use"], "DescriptorName": "Plant Extracts"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["drug effects", "pathology"], "DescriptorName": "Skin"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Jeon J.H., Kwon S.C., Park D., Shin S., Jeong J.H., Park S.Y., Hwang S.Y., Kim Y.B., Joo S.S. Anti-allergic effects of white rose petal extract and anti-atopic properties of its hexane fraction. Arch. Pharm. Res. 2009;32:823\u2013830. doi: 10.1007/s12272-009-1602-6.", "ArticleIdList": ["10.1007/s12272-009-1602-6", "19557358"]}, {"Citation": "Nettis E., Ortoncelli M., Pellacani G., Foti C., Di Leo E., Patruno C., Rongioletti F., Argenziano G., Ferrucci S.M., Macchia L., et al. A Multicenter Study on the Prevalence of Clinical Patterns and Clinical Phenotypes in Adult Atopic Dermatitis. J. Investig. Allergol. Clin. Immunol. 2020;30:448\u2013450. doi: 10.18176/jiaci.0519.", "ArticleIdList": ["10.18176/jiaci.0519", "32376512"]}, {"Citation": "Lee J.H., Ki H.H., Kim D.K., Lee Y.M. Triticum aestivum sprout extract attenuates 2,4dinitrochlorobenzeneinduced atopic dermatitislike skin lesions in mice and the expression of chemokines in human keratinocytes. Mol. Med. Rep. 2018;18:3461\u20133468. doi: 10.3892/mmr.2018.9339.", "ArticleIdList": ["10.3892/mmr.2018.9339", "30066901"]}, {"Citation": "De Benedetto A., Agnihothri R., McGirt L.Y., Bankova L.G., Beck L.A. Atopic dermatitis: A disease caused by innate immune defects? J. Investig. Dermatol. 2009;129:14\u201330. doi: 10.1038/jid.2008.259.", "ArticleIdList": ["10.1038/jid.2008.259", "19078985"]}, {"Citation": "Bylund S., von Kobyletzki L.B., Svalstedt M., Svensson A. Prevalence and Incidence of Atopic Dermatitis: A Systematic Review. Acta Derm. Venereol. 2020;100:adv00160. doi: 10.2340/00015555-3510.", "ArticleIdList": ["10.2340/00015555-3510", "PMC9189744", "32412646"]}, {"Citation": "Yarbrough K.B., Neuhaus K.J., Simpson E.L. The effects of treatment on itch in atopic dermatitis. Dermatol. Ther. 2013;26:110\u2013119. doi: 10.1111/dth.12032.", "ArticleIdList": ["10.1111/dth.12032", "PMC4524501", "23551368"]}, {"Citation": "Carter K.F., Dufour L.T., Ballard C.N. Identifying secondary skin lesions. Nursing. 2004;34:68. doi: 10.1097/00152193-200401000-00060.", "ArticleIdList": ["10.1097/00152193-200401000-00060", "14738076"]}, {"Citation": "Lou H., Lu J., Choi E.B., Oh M.H., Jeong M., Barmettler S., Zhu Z., Zheng T. Expression of IL-22 in the Skin Causes Th2-Biased Immunity, Epidermal Barrier Dysfunction, and Pruritus via Stimulating Epithelial Th2 Cytokines and the GRP Pathway. J. Immunol. 2017;198:2543\u20132555. doi: 10.4049/jimmunol.1600126.", "ArticleIdList": ["10.4049/jimmunol.1600126", "PMC5360537", "28228560"]}, {"Citation": "Eyerich K., Eyerich S. Th22 cells in allergic disease. Allergo J. Int. 2015;24:1\u20137. doi: 10.1007/s40629-015-0039-3.", "ArticleIdList": ["10.1007/s40629-015-0039-3", "PMC4479457", "26120541"]}, {"Citation": "Kawakami T., Ando T., Kimura M., Wilson B.S., Kawakami Y. Mast cells in atopic dermatitis. Curr. Opin. Immunol. 2009;21:666\u2013678. doi: 10.1016/j.coi.2009.09.006.", "ArticleIdList": ["10.1016/j.coi.2009.09.006", "PMC2839879", "19828304"]}, {"Citation": "Amin K. The role of mast cells in allergic inflammation. Respir. Med. 2012;106:9\u201314. doi: 10.1016/j.rmed.2011.09.007.", "ArticleIdList": ["10.1016/j.rmed.2011.09.007", "22112783"]}, {"Citation": "Wang A.X., Xu Landen N. New insights into T cells and their signature cytokines in atopic dermatitis. IUBMB Life. 2015;67:601\u2013610. doi: 10.1002/iub.1405.", "ArticleIdList": ["10.1002/iub.1405", "26178387"]}, {"Citation": "Fujita H. The role of IL-22 and Th22 cells in human skin diseases. J. Dermatol. Sci. 2013;72:3\u20138. doi: 10.1016/j.jdermsci.2013.04.028.", "ArticleIdList": ["10.1016/j.jdermsci.2013.04.028", "23746568"]}, {"Citation": "Rerknimitr P., Otsuka A., Nakashima C., Kabashima K. The etiopathogenesis of atopic dermatitis: Barrier disruption, immunological derangement, and pruritus. Inflamm. Regen. 2017;37:14. doi: 10.1186/s41232-017-0044-7.", "ArticleIdList": ["10.1186/s41232-017-0044-7", "PMC5725646", "29259713"]}, {"Citation": "Caubet C., Jonca N., Brattsand M., Guerrin M., Bernard D., Schmidt R., Egelrud T., Simon M., Serre G. Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J. Invest. Dermatol. 2004;122:1235\u20131244. doi: 10.1111/j.0022-202X.2004.22512.x.", "ArticleIdList": ["10.1111/j.0022-202X.2004.22512.x", "15140227"]}, {"Citation": "Simpson E.L. Atopic dermatitis: A review of topical treatment options. Curr. Med. Res. Opin. 2010;26:633\u2013640. doi: 10.1185/03007990903512156.", "ArticleIdList": ["10.1185/03007990903512156", "20070141"]}, {"Citation": "Tidwell W.J., Fowler J.F., Jr. T-cell inhibitors for atopic dermatitis. J. Am. Acad. Dermatol. 2018;78:S67\u2013S70. doi: 10.1016/j.jaad.2017.12.020.", "ArticleIdList": ["10.1016/j.jaad.2017.12.020", "29248519"]}, {"Citation": "Thomsen S.F. Atopic dermatitis: Natural history, diagnosis, and treatment. ISRN Allergy. 2014;2014:354250. doi: 10.1155/2014/354250.", "ArticleIdList": ["10.1155/2014/354250", "PMC4004110", "25006501"]}, {"Citation": "Dattola A., Bennardo L., Silvestri M., Nistico S.P. What\u2019s new in the treatment of atopic dermatitis? Dermatol. Ther. 2019;32:e12787. doi: 10.1111/dth.12787.", "ArticleIdList": ["10.1111/dth.12787", "30548724"]}, {"Citation": "Mostow E. A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis. J. Am. Acad. Dermatol. 2019 doi: 10.1016/j.jaad.2019.07.091.", "ArticleIdList": ["10.1016/j.jaad.2019.07.091", "29032119"]}, {"Citation": "Thaci D., Salgo R. Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: Facts and controversies. Clin. Dermatol. 2010;28:52\u201356. doi: 10.1016/j.clindermatol.2009.04.001.", "ArticleIdList": ["10.1016/j.clindermatol.2009.04.001", "20082951"]}, {"Citation": "Jeon Y.C. Treatment for an Adult Patient with Psoriasis with Traditional Korean Medicine, Especially Sa-Am Acupuncture and Herbal Medicine. J. Acupunct. Meridian Stud. 2016;9:88\u201392. doi: 10.1016/j.jams.2016.01.008.", "ArticleIdList": ["10.1016/j.jams.2016.01.008", "27079230"]}, {"Citation": "Jo S.Y., Kim M.H., Lee H., Lee S.H., Yang W.M. Ameliorative and Synergic Effects of Derma-H, a New Herbal Formula, on Allergic Contact Dermatitis. Front. Pharmacol. 2020;11:1019. doi: 10.3389/fphar.2020.01019.", "ArticleIdList": ["10.3389/fphar.2020.01019", "PMC7371928", "32760271"]}, {"Citation": "Kim J.H., Kim M.H., Yang G., Huh Y., Kim S.H., Yang W.M. Effects of topical application of Astragalus membranaceus on allergic dermatitis. Immunopharmacol. Immunotoxicol. 2013;35:151\u2013156. doi: 10.3109/08923973.2012.733708.", "ArticleIdList": ["10.3109/08923973.2012.733708", "23083228"]}, {"Citation": "Choi Y.Y., Kim M.H., Kim J.H., Jung H.S., Sohn Y., Choi Y.J., Hwang M.K., Kim S.H., Kim J., Yang W.M. Schizonepeta tenuifolia inhibits the development of atopic dermatitis in mice. Phytother. Res. 2013;27:1131\u20131135. doi: 10.1002/ptr.4833.", "ArticleIdList": ["10.1002/ptr.4833", "22949410"]}, {"Citation": "Chen H.Y., Lin Y.H., Huang J.W., Chen Y.C. Chinese herbal medicine network and core treatments for allergic skin diseases: Implications from a nationwide database. J. Ethnopharmacol. 2015;168:260\u2013267. doi: 10.1016/j.jep.2015.04.002.", "ArticleIdList": ["10.1016/j.jep.2015.04.002", "25865681"]}, {"Citation": "Lee J., Choi Y.Y., Kim M.H., Han J.M., Lee J.E., Kim E.H., Hong J., Kim J., Yang W.M. Topical Application of Angelica sinensis Improves Pruritus and Skin Inflammation in Mice with Atopic Dermatitis-Like Symptoms. J. Med. Food. 2016;19:98\u2013105. doi: 10.1089/jmf.2015.3489.", "ArticleIdList": ["10.1089/jmf.2015.3489", "26305727"]}, {"Citation": "Sohn E.H., Jang S.A., Joo H., Park S., Kang S.C., Lee C.H., Kim S.Y. Anti-allergic and anti-inflammatory effects of butanol extract from Arctium lappa L. Clin. Mol. Allergy. 2011;9:4. doi: 10.1186/1476-7961-9-4.", "ArticleIdList": ["10.1186/1476-7961-9-4", "PMC3045362", "21303540"]}, {"Citation": "Petersen T.K. In vivo pharmacological disease models for psoriasis and atopic dermatitis in drug discovery. Basic Clin. Pharmacol. Toxicol. 2006;99:104\u2013115. doi: 10.1111/j.1742-7843.2006.pto_298.x.", "ArticleIdList": ["10.1111/j.1742-7843.2006.pto_298.x", "16918710"]}, {"Citation": "Kim J., Kim B.E., Leung D.Y.M. Pathophysiology of atopic dermatitis: Clinical implications. Allergy Asthma Proc. 2019;40:84\u201392. doi: 10.2500/aap.2019.40.4202.", "ArticleIdList": ["10.2500/aap.2019.40.4202", "PMC6399565", "30819278"]}, {"Citation": "Sharma L. Diagnostic clinical features of atopic dermatitis. Indian J. Dermatol. Venereol. Leprol. 2001;67:25\u201327.", "ArticleIdList": ["17664694"]}, {"Citation": "Vender R.B. Alternative treatments for atopic dermatitis: A selected review. Skin Ther. Lett. 2002;7:1\u20135.", "ArticleIdList": ["12007013"]}, {"Citation": "Zhu Y., Yu X., Ge Q., Li J., Wang D., Wei Y., Ouyang Z. Antioxidant and anti-aging activities of polysaccharides from Cordyceps cicadae. Int. J. Biol. Macromol. 2020;157:394\u2013400. doi: 10.1016/j.ijbiomac.2020.04.163.", "ArticleIdList": ["10.1016/j.ijbiomac.2020.04.163", "32339570"]}, {"Citation": "Chan Y.S., Cheng L.N., Wu J.H., Chan E., Kwan Y.W., Lee S.M., Leung G.P., Yu P.H., Chan S.W. A review of the pharmacological effects of Arctium lappa (burdock) Inflammopharmacology. 2011;19:245\u2013254. doi: 10.1007/s10787-010-0062-4.", "ArticleIdList": ["10.1007/s10787-010-0062-4", "20981575"]}, {"Citation": "Hanifin J.M., Thurston M., Omoto M., Cherill R., Tofte S.J., Graeber M. The eczema area and severity index (EASI): Assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp. Dermatol. 2001;10:11\u201318. doi: 10.1034/j.1600-0625.2001.100102.x.", "ArticleIdList": ["10.1034/j.1600-0625.2001.100102.x", "11168575"]}, {"Citation": "Ikoma A., Steinhoff M., Stander S., Yosipovitch G., Schmelz M. The neurobiology of itch. Nat. Rev. Neurosci. 2006;7:535\u2013547. doi: 10.1038/nrn1950.", "ArticleIdList": ["10.1038/nrn1950", "16791143"]}, {"Citation": "Rinaldi G. The Itch-Scratch Cycle: A Review of the Mechanisms. Dermatol. Pract. Concept. 2019;9:90\u201397. doi: 10.5826/dpc.0902a03.", "ArticleIdList": ["10.5826/dpc.0902a03", "PMC6502296", "31106010"]}, {"Citation": "Arima K., Ohta S., Takagi A., Shiraishi H., Masuoka M., Ontsuka K., Suto H., Suzuki S., Yamamoto K., Ogawa M., et al. Periostin contributes to epidermal hyperplasia in psoriasis common to atopic dermatitis. Allergol. Int. 2015;64:41\u201348. doi: 10.1016/j.alit.2014.06.001.", "ArticleIdList": ["10.1016/j.alit.2014.06.001", "PMC4793727", "25572557"]}, {"Citation": "Matsunaga Y., Ogura Y., Ehama R., Amano S., Nishiyama T., Tagami H. Establishment of a mouse skin model of the lichenification in human chronic eczematous dermatitis. Br. J. Dermatol. 2007;156:884\u2013891. doi: 10.1111/j.1365-2133.2007.07770.x.", "ArticleIdList": ["10.1111/j.1365-2133.2007.07770.x", "17326747"]}, {"Citation": "Nakahigashi K., Kabashima K., Ikoma A., Verkman A.S., Miyachi Y., Hara-Chikuma M. Upregulation of aquaporin-3 is involved in keratinocyte proliferation and epidermal hyperplasia. J. Investig. Dermatol. 2011;131:865\u2013873. doi: 10.1038/jid.2010.395.", "ArticleIdList": ["10.1038/jid.2010.395", "21191421"]}, {"Citation": "Gu H., Kim W.H., An H.J., Kim J.Y., Gwon M.G., Han S.M., Leem J., Park K.K. Therapeutic effects of bee venom on experimental atopic dermatitis. Mol. Med. Rep. 2018;18:3711\u20133718. doi: 10.3892/mmr.2018.9398.", "ArticleIdList": ["10.3892/mmr.2018.9398", "PMC6131226", "30132547"]}, {"Citation": "Irani A.M., Sampson H.A., Schwartz L.B. Mast cells in atopic dermatitis. Allergy. 1989;44(Suppl. 9):31\u201334. doi: 10.1111/j.1398-9995.1989.tb02452.x.", "ArticleIdList": ["10.1111/j.1398-9995.1989.tb02452.x", "2817313"]}, {"Citation": "Sehra S., Serezani A.P.M., Ocana J.A., Travers J.B., Kaplan M.H. Mast Cells Regulate Epidermal Barrier Function and the Development of Allergic Skin Inflammation. J. Investig. Dermatol. 2016;136:1429\u20131437. doi: 10.1016/j.jid.2016.03.019.", "ArticleIdList": ["10.1016/j.jid.2016.03.019", "PMC4921316", "27021404"]}, {"Citation": "Donetti E., Bedoni M., Boschini E., Dellavia C., Barajon I., Gagliano N. Desmocollin 1 and desmoglein 1 expression in human epidermis and keratinizing oral mucosa: A comparative immunohistochemical and molecular study. Arch. Dermatol. Res. 2005;297:31\u201338. doi: 10.1007/s00403-005-0573-9.", "ArticleIdList": ["10.1007/s00403-005-0573-9", "15926049"]}, {"Citation": "Totsuka A., Omori-Miyake M., Kawashima M., Yagi J., Tsunemi Y. Expression of keratin 1, keratin 10, desmoglein 1 and desmocollin 1 in the epidermis: Possible downregulation by interleukin-4 and interleukin-13 in atopic dermatitis. Eur. J. Dermatol. 2017;27:247\u2013253. doi: 10.1684/ejd.2017.2985.", "ArticleIdList": ["10.1684/ejd.2017.2985", "28524044"]}, {"Citation": "Matsui T., Amagai M. Dissecting the formation, structure and barrier function of the stratum corneum. Int. Immunol. 2015;27:269\u2013280. doi: 10.1093/intimm/dxv013.", "ArticleIdList": ["10.1093/intimm/dxv013", "25813515"]}, {"Citation": "Sandilands A., Sutherland C., Irvine A.D., McLean W.H. Filaggrin in the frontline: Role in skin barrier function and disease. J. Cell Sci. 2009;122:1285\u20131294. doi: 10.1242/jcs.033969.", "ArticleIdList": ["10.1242/jcs.033969", "PMC2721001", "19386895"]}, {"Citation": "O\u2019Regan G.M., Sandilands A., McLean W.H., Irvine A.D. Filaggrin in atopic dermatitis. J. Allergy Clin. Immunol. 2009;124:R2\u2013R6. doi: 10.1016/j.jaci.2009.07.013.", "ArticleIdList": ["10.1016/j.jaci.2009.07.013", "19720209"]}, {"Citation": "Brown S.J., McLean W.H. One remarkable molecule: Filaggrin. J. Investig. Dermatol. 2012;132:751\u2013762. doi: 10.1038/jid.2011.393.", "ArticleIdList": ["10.1038/jid.2011.393", "PMC3378480", "22158554"]}, {"Citation": "Scharschmidt T.C., Man M.Q., Hatano Y., Crumrine D., Gunathilake R., Sundberg J.P., Silva K.A., Mauro T.M., Hupe M., Cho S., et al. Filaggrin deficiency confers a paracellular barrier abnormality that reduces inflammatory thresholds to irritants and haptens. J. Allergy Clin. Immunol. 2009;124:496\u2013506.e6. doi: 10.1016/j.jaci.2009.06.046.", "ArticleIdList": ["10.1016/j.jaci.2009.06.046", "PMC2881668", "19733297"]}, {"Citation": "Lee H.J., Lee S.H. Epidermal permeability barrier defects and barrier repair therapy in atopic dermatitis. Allergy Asthma Immunol. Res. 2014;6:276\u2013287. doi: 10.4168/aair.2014.6.4.276.", "ArticleIdList": ["10.4168/aair.2014.6.4.276", "PMC4077953", "24991450"]}, {"Citation": "Ekholm I.E., Brattsand M., Egelrud T. Stratum corneum tryptic enzyme in normal epidermis: A missing link in the desquamation process? J. Investig. Dermatol. 2000;114:56\u201363. doi: 10.1046/j.1523-1747.2000.00820.x.", "ArticleIdList": ["10.1046/j.1523-1747.2000.00820.x", "10620116"]}, {"Citation": "Morizane S. The Role of Kallikrein-Related Peptidases in Atopic Dermatitis. Acta Med. Okayama. 2019;73:1\u20136. doi: 10.18926/AMO/56452.", "ArticleIdList": ["10.18926/AMO/56452", "30820048"]}, {"Citation": "Egawa G., Kabashima K. Multifactorial skin barrier deficiency and atopic dermatitis: Essential topics to prevent the atopic march. J. Allergy Clin. Immunol. 2016;138:350\u2013358.e1. doi: 10.1016/j.jaci.2016.06.002.", "ArticleIdList": ["10.1016/j.jaci.2016.06.002", "27497277"]}, {"Citation": "Fridman J.S., Scherle P.A., Collins R., Burn T., Neilan C.L., Hertel D., Contel N., Haley P., Thomas B., Shi J., et al. Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. J. Investig. Dermatol. 2011;131:1838\u20131844. doi: 10.1038/jid.2011.140.", "ArticleIdList": ["10.1038/jid.2011.140", "21677670"]}, {"Citation": "He H., Guttman-Yassky E. JAK Inhibitors for Atopic Dermatitis: An Update. Am. J. Clin. Dermatol. 2019;20:181\u2013192. doi: 10.1007/s40257-018-0413-2.", "ArticleIdList": ["10.1007/s40257-018-0413-2", "30536048"]}, {"Citation": "Yasuda T., Fukada T., Nishida K., Nakayama M., Matsuda M., Miura I., Dainichi T., Fukuda S., Kabashima K., Nakaoka S., et al. Hyperactivation of JAK1 tyrosine kinase induces stepwise, progressive pruritic dermatitis. J. Clin. Investig. 2016;126:2064\u20132076. doi: 10.1172/JCI82887.", "ArticleIdList": ["10.1172/JCI82887", "PMC4887165", "27111231"]}, {"Citation": "Brunner P.M., Pavel A.B., Khattri S., Leonard A., Malik K., Rose S., Jim On S., Vekaria A.S., Traidl-Hoffmann C., Singer G.K., et al. Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab. J. Allergy Clin. Immunol. 2019;143:142\u2013154. doi: 10.1016/j.jaci.2018.07.028.", "ArticleIdList": ["10.1016/j.jaci.2018.07.028", "30121291"]}, {"Citation": "Welsch K., Holstein J., Laurence A., Ghoreschi K. Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors. Eur. J. Immunol. 2017;47:1096\u20131107. doi: 10.1002/eji.201646680.", "ArticleIdList": ["10.1002/eji.201646680", "28555727"]}, {"Citation": "Lejeune D., Dumoutier L., Constantinescu S., Kruijer W., Schuringa J.J., Renauld J.C. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J. Biol. Chem. 2002;277:33676\u201333682. doi: 10.1074/jbc.M204204200.", "ArticleIdList": ["10.1074/jbc.M204204200", "12087100"]}, {"Citation": "Bernard F.X., Morel F., Camus M., Pedretti N., Barrault C., Garnier J., Lecron J.C. Keratinocytes under Fire of Proinflammatory Cytokines: Bona Fide Innate Immune Cells Involved in the Physiopathology of Chronic Atopic Dermatitis and Psoriasis. J. Allergy. 2012;2012:718725. doi: 10.1155/2012/718725.", "ArticleIdList": ["10.1155/2012/718725", "PMC3502002", "23193414"]}, {"Citation": "Hanel K.H., Cornelissen C., Luscher B., Baron J.M. Cytokines and the skin barrier. Int. J. Mol. Sci. 2013;14:6720\u20136745. doi: 10.3390/ijms14046720.", "ArticleIdList": ["10.3390/ijms14046720", "PMC3645662", "23531535"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "2", "Day": "5"}, {"Year": "2021", "Month": "2", "Day": "17"}, {"Year": "2021", "Month": "2", "Day": "24"}, {"Year": "2021", "Month": "3", "Day": "3", "Hour": "1", "Minute": "2"}, {"Year": "2021", "Month": "3", "Day": "4", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "4", "Day": "20", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "2", "Day": "26"}], "PublicationStatus": "epublish", "ArticleIdList": ["33652999", "PMC7956340", "10.3390/ijms22052359", "ijms22052359"]}}], "PubmedBookArticle": []}